- My Intelligent Machines (MIMS) recently announced it closed $2.6 million in a seed round of funding from Anges Québec, Anges Québec Capital, Desjardins Capital, Consortium MEDTEQ, Real Ventures, and StandUp Ventures
Montreal-based My Intelligent Machines (MIMS) has announced it closed $2.6 million in a seed round of funding from Anges Québec, Anges Québec Capital, Desjardins Capital, Consortium MEDTEQ, Real Ventures, and StandUp Ventures. With this round of funding, MIMS is planning to develop turnkey and integrated solutions enabling life scientists without expertise in bioinformatics or data sciences to stratify human, animal, and plant populations.
“MIMS sets itself apart from other AI startups, because of our ability to leverage what we call ‘fat data’ using AI, which is very difficult to do. These data are of great strategic value for companies in the biopharmaceutical agricultural technology sectors” said My Intelligent Machines co-founder and CEO Sarah Jenna.
MIMS offers a SaaS platform for analyzing omics data by using different types of artificial intelligence in order to facilitate the use by non-computer scientists of bioinformatics and very complex data science methodologies to generate predictive models for companies from the biopharmaceutical and agtech sectors.
“The particularity of MIMS lies in its innovation in artificial intelligence within the health sector. We are convinced that the forward-thinking nature of this company is the key their success. MIMS will contribute to life sciences companies that are ready to welcome the artificial intelligence era. We are witnessing a significant change” added Jean-Marc Rousseau of Anges Québec.
Real Ventures — through its Orbite investment strategy in the pre-seed and seed stage — is supporting MIMS following its participation in the FounderFuel acceleration program in 2017.
“It is still too rare in Quebec to see university professors, with the specialized expertise of their field, go from academia to entrepreneurship. It was a great pleasure to see the shock of ideas and the challenge to deliver, the theoretical expertise and the practical implementation, the evolution of the leadership under the guidance of Sarah Jenna and her co-founders. This is for us the validation of our thesis of investment in scientists, engineers, and hackers, it’s just a milestone in the course, but it’s very promising” explained Sylvain Carle of Real Ventures.
MIMS is currently collaborating with two flagship projects to demonstrate the full potential of its solution in the field of health and agtech. The first is a triple-negative breast cancer clinical trial in collaboration with the Jewish General Hospital — which aims to identify groups of patients most receptive to chemotherapy treatment.
The second is a collaboration with a dairy consortium also involving research laboratories and the Valacta Center of Expertise in Milk Production to stratify cow populations in order to develop more efficient recommendation systems for farmers, enabling them to thus to increase their profitability.
Founded by Jenna, Mickaël Camus, and Abdoulaye Baniré Diallo, MIMS is currently collaborating with two flagship projects to demonstrate the full potential of its solution in the field of health and agtech. The first is a triple-negative breast cancer clinical trial in collaboration with the Jewish General Hospital — which aims to identify groups of patients most receptive to chemotherapy treatment.
The second is a collaboration with a dairy consortium also involving research laboratories and the Valacta Center of Expertise in Milk Production to stratify cow populations in order to develop more efficient recommendation systems for farmers, enabling them to thus to increase their profitability.
